[1]Travis WD，Brambilla E，NoguchiM，et al.The new IASLC/ATS/ERS internationalmultidisciplinary lung adenocarcinoma classification.J Thorac Oncol，2011，6：244-285.

[2]Parkin DM，Whelan SL，Ferlay J，et al.Cancer Incidence in Five Continents，Vol.VIII.Lyon：IARC Press，2002：155.

[3]Quinn D，Gianlupi A，Broste S，et al.The changing radiographic presentation of bronchogenic carcinoma with reference to cell types.Chest，1996，110：1474-1479.

[4]Hussain AN.Robbins and Cotran pathologic basis of disease.8th edition.Philadelphia：Saunders Elsevier，2010，677-737.

[5]Travis WD，Brambilla E，Muller-Hermelink HK，et al.Pathology and genetics：tumours of the lung，pleura，thymus and heart.Lyon（France）：IARC，2004.

[6]Travis WD.Pathology of Lung Cancer.Clin ChestMed，2011，32669-32692.

[7]TravisWD，Colby TV，Corrin B，et al，In collaboration with L.H.Sobin and pathologists from 14 countries.Histological Typing of Lung and Pleural Tumors.3rd edition.Berlin：Springer，1999.

[8]Davies SJ，Gosney JR，Hansell DM，et al.Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia：an under-recognised spectrum of disease.Thorax，2007，62：248-252.

[9]Lantuejoul S，Salameire D，Salon C，et al.Pulmonary preneoplasia-sequential molecular carcinogenetic events.Histopathology，2009，54：43-54.

[10]Carey FA，Wallace WA，Fergusson RJ，et al.Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma：a clinicopathological study of 10 cases.Thorax，1992，47：1041-1043.

[11]Weng S，Tsuchiya E，Satoh Y，et al.Multiple atypical adenomatous hyperplasia of type IIpneumonocytes and bronchio-alveolar carcinoma.Histopathology，1990，16：101-103.

[12]Nakanishi K.Alveolar epithelial hyperplasia and adenocarcinoma of the lung.Arch Pathol Lab Med，1990，114：363-368.

[13]Nakahara R，Yokose T，NagaiK，et al.Atypical adenomatous hyperplasia of the lung：a clinicopathological study of118 cases including caseswithmultiple atypical adenomatous hyperplasia.Thorax，2001，56：302-305.

[14]Miller RR.Bronchioloalveolar cell adenomas.Am JSurg Pathol，1990，14：904-912.

[15]Maeshima AM，TochigiN，Yoshida A，etal.Clinicopathologic analysis ofmultiple（five ormore）atypical adenomatous hyperplasias（AAHs）of the lung：evidence for the AAH-adenocarcinoma sequence.J Thorac Oncol，2010，5：466-471.

[16]MoriM，Rao SK，Popper HH，et al.Atypical adenomatous hyperplasia of the lung：a probable forerunner in the development of adenocarcinoma of the lung.Mod Pathol，2001，14：72-84.

[17]Kitamura H，Kameda Y，Ito T，et al.Atypical adenomatous hyperplasia of the lung.Implications for the pathogenesis of peripheral lung adenocarcinoma.Am J Clin Pathol，1999，111：610-622.

[18]Nakanishi K，Kawai T，Kumaki F，etal.Expression of human telomerase RNA componentand telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung.Hum Pathol，2002，33：697-702.

[19]Koga T，Hashimoto S，Sugio K，et al.Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with fociof high-grade atypical adenomatous hyperplasia.Am J Clin Pathol，2002，117：464-470.

[20]Nakayama H，Noguchi M，Tsuchiya R，et al.Clonal growth of atypical adenomatous hyperplasia of the lung：cytofluorometric analysis of nuclear DNA content.Mod Pathol，1990，3：314-320.

[21]Niho S，Yokose T，Suzuki K，etal.Monoclonality of atypical adenomatous hyperplasia of the lung.Am J Pathol，1999，154：249-254.

[22]Sakamoto H，Shimizu J，Horio Y，et al.Disproportionate representation of KRASgenemutation in atypical adenomatous hyperplasia，but even distribution of EGFR genemutation from preinvasive to invasive adenocarcinomas.J Pathol，2007，212：287-294.

[23]WestraWH，Baas IO，Hruban RH，et al.K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.Cancer Res，1996，56：2224-2228.

[24]Kohno T，Kunitoh H，Suzuki K，et al.Association of KRAS polymorphismswith risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias.Carcinogenesis，2008，29：957-963.

[25]Yoshida Y，Shibata T，Kokubu A，et al.Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.Lung Cancer，2005，50：1-8.

[26]Kitamura H，Kameda Y，Nakamura N，et al.Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma.Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen.Am J Surg Pathol，1996，20：553-562.

[27]Takamochi K，Ogura T，Suzuki K，et al.Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung.Am J Pathol，2001，159：1941-1948.

[28]Licchesi JD，Westra WH，Hooker CM，et al.Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.Clin Cancer Res，2008，14：2570-2578.

[29]Seki N，Takasu T，Mandai K，et al.Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.Clin Cancer Res，2002，8：3046-3053.

[30]Licchesi JD，Westra WH，Hooker CM，et al.Epigenetic alteration ofWnt pathway antagonists in progressive glandular neoplasia of the lung.Carcinogenesis，2008，29：895-904.

[31]Kerr KM，MacKenzie SJ，Ramasami S，et al.Expression of Fhit，cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma.J Pathol，2004，203：638-644.

[32]Colby TV，KossMN，TravisWD.Tumors of the lower respiratory tract；Armed Forces Institute of Pathology fascicle，third series.Washington，DC：Armed Forces Institute of Pathology，1995.

[33]Funai K，Yokose T，Ishii G，et al.Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung.Am J Surg Pathol，2003，27：978-984.

[34]Katzenstein AL，Prioleau PG，Askin FB，et al.The histologic spectrum and significance of clear-cell change in lung carcinoma.Cancer，1980，45：943-947.

[35]Brambilla E，Moro D，Veale D，et al.Basal cell（basaloid）carcinoma of the lung-a new morphologic and phenotypic entity with separate prognostic significance.Hum Pathol，1992，23：993-1003.

[36]Moro D，Brichon PY，Brambilla E，et al.Basaloid bronchial carcinoma-a histologic group with a poor prognosis.Cancer，1994，73：2734-2739.

[37]Moro-Sibilot D，Lantuejoul S，Diab S，et al.Lung carcinomaswith a basaloid pattern：a study of 90 cases focusing on their poor prognosis.Eur Respir J，2008，31：854-859.

[38]Dulmet-Brender E，Jaubert F，Huchon G.Exophytic endobronchial epidermoid carcinoma.Cancer，1986，57：1358-1364.

[39]Sherwin RP，Laforet EG，Strieder JW.Exophytic endobronchial carcinoma.J Thorac Cardiovasc Surg，1962，43：716-730.

[40]Maeshima AM，Maeshima A，Asamura H，et al.Histologic prognostic factors for small-sized squamous cell carcinomas of the peripheral lung.Lung Cancer，2006，52：53-58.

[41]Watanabe Y，Yokose T，Sakuma Y，et al.Alveolar space filling ratio as a favorable prognostic factor in small peripheral squamous cell carcinoma of the lung.Lung Cancer，2011，73（2）：217-221.

[42]Yousem SA.Peripheral squamous cell carcinoma of lung：patterns of growth with particular focus on airspace filling.Hum Pathol，2009，40：861-867.

[43]Bai Y，Kim JY，Watters JM，etal.Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations.Cancer Res，2014.

[44]Yashima H，Shimizu K，Araki T，et al.Assessment of DDR2，BRAF，EGFR and KRASmutations as therapeutic targets in non-adenocarcinoma lung cancer patients.Mol Clin Oncol，2014，2（5）：714-718.

[45]Seo AN，Jin Y，Lee HJ，et al.FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.Virchows Arch，2014，465（5）：547-558.

[46]Travis WD，Travis LB，Devesa SS.Lung cancer.Cancer，1995，75：191-202.

[47]Altekruse SF，Kosary CL，Krapcho M，et al.SEER Cancer Statistics Review（CSR）1975-2011[EB/ OL].

[48]Kodama T，Shimosato Y，Koide T，et al.Endobronchial polypoid adenocarcinoma of the lung.Histological and ultrastructural studies of five cases.Am J Surg Pathol，1984，8：845-854.

[49]Yoshizawa A，Motoi N，Riely GJ，et al.Impact of proposed IASLC/ATS/ERSclassification of lung adenocarcinoma：prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.Mod Pathol，2011，24（5）：653-664.

[50]Sica G，Yoshizawa A，Sima CS，et al.A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors.Am J Surg Pathol，2010，34：1155-1162.

[51]Amin MB，Tamboli P，Merchant SH，etal.Micropapillary component in lung adenocarcinoma：a distinctive histologic featurewith possible prognostic significance.Am J Surg Pathol，2002，26：358-364.

[52]Miyoshi T，Satoh Y，Okumura S，et al.Early-stage lung adenocarcinomaswith amicropapillary pattern，a distinct pathologic marker for a significantly poor prognosis.Am J Surg Pathol，2003，27：101-109.

[53]Kamiya K，Hayashi Y，Douguchi J，et al.Histopathological features and prognostic significance of themicropapillary pattern in lung adenocarcinoma.Mod Pathol，2008，21：992-1001.

[54]Kawakami T，Nabeshima K，Makimoto Y，et al.Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung：usefulness as prognostic factors.Mod Pathol，2007，20：514-521.

[55]Sanchez-Mora N，Presmanes MC，Monroy V，et al.Micropapillary lung adenocarcinoma：a distinctive histologic subtype with prognostic significance.Case series.Hum Pathol，2008，39：324-330.

[56]Tsutsumida H，Nomoto M，Goto M，et al.A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma，and reduced surfactantapoprotein A expression in themicropapillary pattern is an excellent indicator of a poor prognosis.Mod Pathol，2007，20：638-647.

[57]Nitadori J，Bograd AJ，Kadota K，et al.Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.J Natl Cancer Inst，2013，105（16）：1212-1220.

[58]Cohen PR，Yoshizawa A，Motoi N，et al.Signet ring cell features（SRCF）in lung adenocarcinoma：a cytologic feature or a histologic subtype？.Mod Pathol，2010，23：400A.

[59]Deshpande CG，Yoshizawa A，Motoi N，et al.Clear cell change in lung adenocarcinoma：a cytologic change rather than a histologic variant.Mod Pathol，2009，22：352A.

[60]Watanabe S，Watanabe T，Arai K，et al.Results ofwedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography.Ann Thorac Surg，2002，73：1071-1075.

[61]SakuraiH，Dobashi Y，Mizutani E，etal.Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter：a prognostic assessment.Ann Thorac Surg.2004，78：1728-1733.

[62]Vazquez M，Carter D，Brambilla E，et al.Solitary and multiple resected adenocarcinomas after CT screening for lung cancer：histopathologic features and their prognostic implications.Lung Cancer，2009，64：148-154.

[63]Yamato Y，Tsuchida M，Watanabe T，et al.Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung.Ann Thorac Surg，2001，71：971-974.

[64]Yoshida J，Nagai K，Yokose T，et al.Limited resection trial for pulmonary ground-glass opacity nodules：fifty-case experience.J Thorac Cardiovasc Surg，2005，129：991-996.

[65]Koike T，Togashi K，Shirato T，etal.Limited resection or noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination.Ann Thorac Surg，2009，88：1106-1111.

[66]Yim J，Zhu LC，Chiriboga L，et al.Histologic features are important prognostic indicators in early stages lung adenocarcinomas.Mod Pathol，2007，20：233-241.

[67]Borczuk AC，Qian F，Kazeros A，et al.Invasive size is an independent predictor of survival in pulmonary adenocarcinoma.Am J Surg Pathol，2009，33：462-469.

[68]Vazquez M，Carter D，Brambilla E，et al.Solitary and multiple resected adenocarcinomas after CT screening for lung cancer：histopathologic features and their prognostic implications.Lung Cancer，2009，64：148-154.

[69]Lee HY，Han J，Lee KS，et al.Lung adenocarcinoma as a solitary pulmonary nodule：prognostic determinants of CT，PET，and histopathologic findings.Lung Cancer，2009，66：379-385.

[70]okose T，Suzuki K，Nagai K，et al.Favorable and unfavorablemorphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter.Lung Cancer，2000，29：179-188.

[71]Lin DM，Ma Y，Zheng S，et al.Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma.Histol Histopathol，2006，21：627-632.

[72]Yoshizawa A，Motoi N，Riely GJ，et al.Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma：prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.Mod Pathol，2011，24（5）：653-664.

[73]Sica G，Yoshizawa A，Sima CS，etal.A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors.Am J Surg Pathol，2010，34：1155-1162.

[74]Terry J，Leung S，Laskin J，et al.Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.Am J Surg Pathol，2010，34（12）：1805-1811.

[75]Kim MJ，Shin HC，Shin KC，et al.Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung：tissuem icroarray assay in resected lung cancer specimens.Ann Diagn Pathol，2013，17（1）：85-90.

[76]Rekhtman N，Ang DC，Sima CS，et al.Immunohistochem ical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.Mod Pathol，2011，24（10）：1348-1359.

[77]Rekhtman N，Brandt SM，Sigel CS，et al.Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma：high accuracy of tumor subtyping and feasibility of EGFR and KRASmolecular testing.J Thorac Oncol，2011，6（3）：451-458.

[78]Sigel CS，Friedlander MA，Zakowski MF，et al.Subtyping of non-small cell lung carcinoma（NSCLC）：comparison of cytology and small biopsy specimens.Mod Pathol，2010，23：414A.

[79]Nicholson AG，Gonzalez D，Shah P，et al.Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologicmaterial，using a panel ofmucin staining，TTF-1，cytokeratin 5/6，and P63，and EGFRmutation analysis.J Thorac Oncol，2010，5：436-441.

[80]Zhang X，Zhao Y，Wang M，et al.Detection and comparison ofepidermal growth factor receptormutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer.Lung Cancer，2008，60：175-182.

[81]ZakowskiMF，Hussain S，PaoW，etal.Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.Arch Pathol Lab Med，2009，133：470-477.

[82]Wu SG，Gow CH，Yu CJ，et al.Frequent EGFRmutations inmalignantp leural effusion of lung adenocarcinoma.Eur Respir J，2008，32：924-930.

[83]Nicholson AG，Gonzalez D，Shah P，etal.Refining the diagnosis and EGFR status of non-small cell carcinoma in biopsy and cytologic material，using a panel of mucin staining，TTF-1，cytokeratin 5/6，and P63，and EGFRmutation analysis.J Thorac Oncol，2010，5：436-441.

[84]Carter N，Nelson F，Gosney JR，et al.Ultrastructural heterogeneity in undifferentiated bronchial carcinoma.J Pathol，1993，171：53-57.

[85]Churg A.The fine structure of large cell undifferentiated carcinoma of the lung.Evidence for its relation to squamous cell carcinomas and adenocarcinomas.Hum Pathol，1978，9：143-156.

[86]Chan JKC，Hui PK，Tsang WYW，et al.Primary lymphoepithelioma-like carcinoma of the lung-a clinicopathologic study of11 cases.Cancer，1995，76：413-422.

[87]Chen FF，Yan JJ，LaiWW，et al.Epstein-Barr virus-associated nonsmall cell lung carcinoma：Undifferentiated‘lymphoepithelioma-like’carcinoma as a distinct entity with better prognosis.Cancer，1998，82：2334-2342.

[88]Han AJ，Xiong M，Gu YY，etal.Lymphoepithelioma-like carcinoma of the lungwith a better prognosis. A clinicopathologic study of 32 cases.Am J Clin Pathol，2001，115：841-850.

[89]Chang YL，Wu CT，Shih JY，et al.New aspects in clinicopathologic and oncogene studiesof23 pulmonary lymphoepithelioma-like carcinomas.Am J Surg Pathol，2002，26：715-723.

[90]Wockel W，Hofler G，Popper HH，et al.Lymphoepithelioma-like carcinoma of the lung.Pathol Res Pract，1995，191：1170-1174.

[91]Morbini P，Riboni R，Tomaselli S，et al.EBER-and LMP-1-expressing pulmonary lymphoepitheliomalike carcinoma in a Caucasian patientv.Hum Pathol，2003，34：623-625.

[92]Takamori S，NoguchiM，Morinaga S，etal.Clinicopathologic characteristics of adenosquamous carcinoma of the lung.Cancer，1991，67：649-654.

[93]Shimizu J，Oda M，HayashiY，etal.A clinicopathological study of resected cases of adenosquamous carcinoma of the lung.Chest，1996，109：989-994.

[94]Dacic S，Finkelstein SD，Sasatomi E，et al.Molecular pathogenesis of pulmonary carcinosarcoma as determined bymicrodissection-based allelotyping.Am J Surg Pathol，2002，26：510-516.

[95]Thompson L，Chang B，Barsky SH，et al.Monoclonal origins of malignantmixed tumors（carcinosarcomas）：evidence for a divergent histogenesis.Am J Surg Pathol，1996，20：277-285.